Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer to Provide Testing for BioMarin Program in Mexico

NEW YORK – BioMarin has chosen PerkinElmer to provide testing in support of the biopharmaceutical firm's sponsored testing program for patients in Mexico, PerkinElmer said on Wednesday.

Specifically, the testing program is aimed at Batten disease and mucopolysaccharidosis (MPS)  disorders and is designed to help patients and clinicians by providing tests for identifying MPS IVA, also called Morquio A syndrome; MPS VI, or Maroteaux-Lamy syndrome; and CLN2, or late infantile neuronal ceroid lipofuscinosis type 2 disease.

PerkinElmer will provide biochemical and genetic testing to patients in Mexico suspected of having Batten disease or an MPS condition, with funding provided by BioMarin. Patients in San Rafael, California-based BioMarin's testing program will receive biochemical screening, followed by confirmatory genetic testing as necessary. All testing will use dried blood spots, Waltham, Massachusetts-based PerkinElmer said.

Financial and other terms of the agreement were not disclosed.

The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.